Methods and compositions for treating tumors with TTFields and sorafenib

US11179322B2 · kind B2 · utility

Assignee

• Novocure GMBH · CH

Inventors

• Karnit Gotlib · Tirat Karmel, IL
• Einav ZEEVI · Jerusalem, IL
• Rosa S. SCHNAIDERMAN · Haifa, IL
• Tali Voloshin-Sela · Haifa, IL
• Moshe Giladi · Haifa, IL
• Adrian Kinzel · Bochum, DE
• Eilon Kirson · Ramat HaSharon, IL
• Uri Weinberg · Haifa, IL
• Yoram Palti · Haifa, IL
• Shiri Davidi · Haifa, IL

Key dates

• Filing date: Jul 9, 2019
• Grant date: Nov 23, 2021
• Expiry date: Jul 9, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61N1/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Viability of cancer cells (e.g., hepatocellular carcinoma cells) can be reduced by administering sorafenib to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Viability of cancer cells (e.g., hepatocellular carcinoma cells) disposed in a body of a living subject can be reduced by administering sorafenib to the subject and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Notably, experiments show that the combination of sorafenib and the alternating electric field produces synergistic results both in vitro and in vivo.